SCEMBLIX targets the abnormal protein that causes Ph+ CML-CP differently
SCEMBLIX is thought to work by binding to a different site (myristoyl pocket) to help block the activity of the abnormal protein that causes Ph+ CML-CP.
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) is caused by a continuously active abnormal protein (BCR-ABL) that leads to uncontrolled growth of abnormal white blood cells (also known as leukemic cells).
All other currently approved tyrosine kinase inhibitors (TKIs) bind to this abnormal protein at a site known as the ATP binding site to help block the protein's activity.
SCEMBLIX targets a different site of this abnormal protein to help block the protein's activity.
SCEMBLIX is the only treatment that is thought to bind to a different site to help block the activity of the abnormal protein that causes Ph+ CML-CP.
ATP, adosine triphosphate.
